AI Operators: Building Pharma’s Next Digital Growth Engine

AI Operator in Pharma

Pharma has spent the past decade teaching artificial intelligence (AI) to recognize patterns, identify risks, and generate insights from increasingly complex data. Models can flag safety signals, predict trial dropout, prioritize commercial opportunities, and surface relevant information for scientific and operational teams. Yet much of this intelligence still stops at the point of recommendation. People must take the insight, move between systems, assemble the required information, and initiate the next step. A new class of agentic AI systems, referred to in this article as AI operators, is beginning to change that model by connecting intelligence with controlled workflow execution. Explore how an Agent Factory in Pharma drives autonomous decision-making across development and pharmacovigilance.

An AI operator can move beyond recommendations to perform defined actions within enterprise workflows. It might access an authorized customer relationship management (CRM) workflow, retrieve information, prepare a follow-up, update a record, or route work for approval. These actions occur within predefined permissions, governance controls, and human oversight rather than through unrestricted autonomy. For pharma organizations, this creates an opportunity to reduce the operational gap between insight and execution while maintaining the accountability required in regulated environments.

The Problem: Insight Has Outpaced Execution

Most pharma organizations already generate more analytical insight than their teams can efficiently act on. A predictive model may tell a commercial team which healthcare professionals are likely to need specific information, but someone may still need to access several systems, gather supporting material, prepare the outreach, and route it through approval before anything happens. The bottleneck was never insight. It was the manual handoff between insight and action. As analytical capabilities improve, this operational gap becomes more visible because organizations can identify opportunities faster than existing processes allow them to respond.

The same challenge appears across the pharma value chain. Clinical operations teams can identify sites falling behind enrollment targets but may still spend significant time gathering supporting data. Medical Affairs teams can identify patterns in field inquiries but must assemble appropriate and approved responses. Commercial teams may have sophisticated segmentation models but lack the operational capacity to execute personalized workflows efficiently across channels. In each case, the challenge is not simply analysis. It is the orchestration of people, data, systems, permissions, and approval processes required to turn an insight into action.

What Is an AI Operator?

An AI operator is not simply a larger chatbot or another label for every AI assistant. For this article, an AI copilot refers primarily to a system that assists a person by generating information, recommendations, summaries, or draft content. An AI operator refers to an agentic system that can also execute specific workflow actions through controlled enterprise tools and integrations. Terms such as “copilot,” “agent,” and “operator” are not universally standardized technical categories, so the distinction here focuses on the level of workflow execution the system is permitted to perform.

For example, a copilot might prepare a suggested response for a Medical Affairs professional and wait for that person to move it into the appropriate workflow. An operator could retrieve approved source material, assemble the response, attach supporting references, place the draft into the relevant system, and route it to a qualified reviewer. The professional still makes the consequential decision and retains accountability for the final output. The operator handles much of the repetitive retrieval, assembly, and routing required to reach that decision.

How an AI Operator in Pharma Works

A production-oriented AI operator typically combines perception, planning, tool use, execution, and human oversight within a controlled workflow. The system first interprets structured and unstructured inputs, including documents, database records, workflow history, and other approved information sources. It uses this context to understand the current state of a task, break the objective into smaller steps, and determine which approved tool or system each step requires. When information is missing, or an unexpected result falls outside defined boundaries, the operator should stop or escalate rather than improvise without control.

The implementation of AI Operator in pharma occurs through governed enterprise integrations. These may include application programming interfaces (APIs), workflow connectors, approved automation interfaces, or database tools. In pharma, connected systems could include Clinical Trial Management Systems (CTMS), Laboratory Information Management Systems (LIMS), customer relationship management platforms, Electronic Data Capture (EDC) systems, safety databases, document management platforms, and literature repositories. The defining characteristic is not a particular integration method. It is the operator’s ability to perform permitted actions through controlled interfaces while preserving traceability.

Human oversight completes the architecture. A qualified person should remain responsible wherever an output can influence a patient, regulatory submission, scientific conclusion, external communication, or another consequential decision. The operator can perform retrieval, assembly, routing, and other repeatable work, while qualified professionals retain judgment and accountability at defined checkpoints. This allows organizations to reduce unnecessary manual effort without treating automation as a substitute for professional responsibility.

How the Workflow Looks in Practice

Consider a medical information request received through a call center. In a traditional process, a medical information specialist may classify the inquiry, search approved internal material, review relevant literature, prepare a response, verify supporting information, and route the draft for medical review. An AI operator can support the mechanical middle of that workflow by retrieving approved content and literature, assembling a draft against authorized response material, attaching supporting sources, and routing the result to the appropriate specialist.

The specialist then reviews the evidence, edits the response where necessary, and provides the required approval. The operator has removed search and assembly time, not the judgment. The same pattern can extend to literature review triage, clinical site monitoring, regulatory document assembly, and controlled commercial workflows. In each case, the objective is not to remove the responsible professional. It is to automate repeatable activities around that professional so human attention remains focused on expertise, interpretation, and accountability.

What Distinguishes a Production-Grade AI Operator?

A useful prototype is not necessarily a production-ready system. Once an operator can interact with enterprise workflows, controls such as defined context of use, least-privilege permissions, action logging, human checkpoints, exception handling, model and data lineage, and continuous monitoring become fundamental. These controls establish what the operator can access, what it can change, when it must stop, and when a qualified person must intervene. They also provide the traceability needed to understand how a particular output or action was produced.

These controls align with current regulatory thinking. The U.S. Food and Drug Administration (FDA) uses a risk-based credibility framework for AI models supporting regulatory decision-making that begins with a clearly defined context of use. The January 2026 Good AI Practice principles developed jointly by the FDA and the European Medicines Agency (EMA) similarly emphasize context of use, human-centric design, data governance, performance assessment, and lifecycle management. These principles reinforce an important point: responsible deployment depends on the system surrounding the model, not simply on model performance.

Where the Economic Opportunity Comes From

The economic opportunity for AI in life sciences is significant, with potential value spanning pharmaceutical and medical technology activities, including commercial functions. McKinsey’s analysis of AI in life sciences highlights the broader potential for AI to create value across the industry.

However, this potential should not be viewed as guaranteed savings or revenue for individual organizations. The value an organization ultimately realizes will depend on factors such as data readiness, workflow design, technology integration, governance, user adoption, and organizational change.

For organizations evaluating AI operators, the better question is which workflows contain enough repetitive and measurable work for controlled automation to create meaningful improvement without introducing unacceptable risk. One published example comes from AI-assisted literature review. Founder and CEO of CapeStart, Gaugarin Oliver, reported in Pharmaceutical Executive that specific AI-assisted review workflows completed reviews up to 40 percent faster, with approximately 90 percent accuracy in title and abstract screening and more than 80 percent accuracy in summarization and data extraction. These results describe specific workflows and should not be treated as universal performance guarantees.

Use Cases 

The strongest early AI operator candidates tend to involve substantial repetitive retrieval or assembly work, rely on clearly defined sources of truth, produce measurable outcomes, and already contain human approval points. Medical information and inquiry response is one example because the workflow combines high request volumes, controlled source material, and explicit review requirements. Literature review and evidence synthesis offers a similar pattern because retrieval, screening support, extraction preparation, evidence organization, and source tracking contain repeatable tasks while scientific judgment remains with qualified reviewers.

Other candidates include field team enablement, clinical trial site monitoring, and regulatory document assembly. Operators can assemble approved call preparation materials, consolidate permitted customer information, surface enrollment or data quality issues from CTMS and EDC platforms, and retrieve source information for regulatory documents. Learn more about the new era of data extraction in life sciences transitioning from traditional NER to AI agents. These applications can reduce the effort required to move information between systems, but each introduces different privacy, promotional, scientific, and regulatory considerations. Responsible functions must therefore retain authority over interpretation and consequential decisions.

AI Operators Vs Earlier Automation Approaches

AI operators do not replace every existing automation technology. Rules-based automation, robotic process automation (RPA), copilots, and agentic systems are suited to different kinds of work and can coexist within the same architecture. Rules-based automation remains effective when processes are stable and predictable, while copilots are useful for retrieval, drafting, summarization, and decision support. Operators become more relevant when workflows require contextual interpretation and controlled execution across multiple systems.

The important distinction is not whether one technology is more intelligent. It is how much autonomy the system receives, how predictable the underlying workflow is, and what controls surround its actions. Deterministic automation may remain the better engineering choice when behavior can be defined precisely. An operator becomes useful when a workflow requires contextual interpretation but can still be bounded through permissions, policies, monitoring, and human escalation.

Build Around Identity and Permissions

Giving an AI system permission to act creates a different security problem from giving it permission only to read. Organizations should apply the principle of least privilege, giving each operator only the data access and actions required for its defined context of use. Separate service identities, scoped credentials, action-level permissions, authentication controls, and rapid revocation mechanisms can further reduce risk. An operator should never receive broad system access simply because a workflow might eventually require it. Read more on architecting the Agent Factory beyond GenAI for enterprise pharma governance.

The distinction matters because a compromised or misdirected system with read access can expose information, while a system with write access can change business state. An operator that can update CRM records, route documents, or modify enterprise data therefore requires controls extending beyond model safety. Identity management, authorization, credential handling, logging, and monitoring need to be treated as part of the AI architecture from the beginning.

Evaluate Before Granting Production Autonomy

Operators should not move directly from prototype to unrestricted production use. A safer progression is offline evaluation → sandbox testing → shadow mode → limited production → monitored expansion. Offline evaluation tests the operator against representative historical tasks, while sandbox testing exposes it to realistic integrations without altering live records. Shadow mode allows teams to compare proposed actions with decisions made by qualified users before the system receives authority to execute consequential actions.

Limited production can then introduce carefully scoped, lower-risk actions with explicit monitoring and escalation rules. Permissions should expand only when workflow-level evidence supports doing so. This approach treats autonomy as something the system earns through demonstrated performance and control rather than something granted simply because the underlying model performs well on a benchmark.

Best Practices for Responsible Deployment

Responsible deployment begins with a narrow context of use. Teams should define what the operator is intended to do, which users it supports, which systems it can access, which actions are prohibited, and what decisions remain outside its authority. Human checkpoints should then be placed where risk actually occurs. Reviewing every low-risk intermediate step can erase productivity gains, while removing human review entirely can create unacceptable risk.

Organizations should also record relevant data sources, tool calls, workflow actions, versions, exceptions, and human approvals. Unexpected system states, conflicting source information, missing approved content, permission failures, or material uncertainty should trigger escalation rather than improvisation. Most importantly, measure the workflow, not just the model. Cycle time, correction rates, rework, escalation rates, execution failures, approval turnaround, and successful end-to-end completion provide a more meaningful picture of operational value than model accuracy alone.

Risks and Limitations

AI operators introduce risks that traditional analytical AI systems may not. Tool access creates a larger attack surface because a system that can update an enterprise platform carries different implications from one that only reads information. Autonomy can also amplify mistakes. A poor recommendation may affect one decision, while a poorly controlled action can affect multiple records or downstream systems. Access scoping, credential management, rate limits, approval gates, monitoring, and safe-stop behavior therefore become important production controls.

Organizations should also avoid assuming that workflow data automatically becomes training data or that performance transfers across environments. Reusing workflow data may depend on privacy requirements, data governance, intellectual property considerations, security controls, and contractual restrictions. Likewise, vendor-reported results describe particular models, datasets, tasks, and workflows. Performance achieved in one therapeutic area or evidence corpus should not be assumed to transfer unchanged to another. Local evaluation remains essential.

The Regulatory Landscape

The FDA’s January 2025 draft guidance, Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products, proposes a risk-based credibility framework for AI models used to support regulatory decisions. The framework centers on a specific context of use. In January 2026, the FDA and EMA also published 10 Guiding Principles of Good AI Practice in Drug Development covering areas such as human-centric design, risk-based approaches, context of use, data governance, performance assessment, and lifecycle management.

The European Union Artificial Intelligence Act (EU AI Act) creates another compliance framework for organizations developing or deploying AI in Europe. Obligations for providers of general-purpose AI (GPAI) models began applying on August 2, 2025. Under the current European Commission AI Act implementation framework, organizations need to assess applicable requirements according to the AI system’s classification, intended use, implementation timeline, and relationship to regulated products. Pharma organizations should therefore evaluate each operator according to its actual function and jurisdiction rather than assuming a single AI compliance pathway.

Where AI Operators Should Not Be Used

Not every workflow needs an operator, and maximizing autonomy should not be the objective. Rules-based software may be safer, cheaper, and easier to validate when a process is stable and deterministic. A copilot may also be preferable when the primary need is drafting, summarization, or information retrieval and there is little benefit in allowing the system to execute actions. Choosing an operator simply because agentic AI is available can introduce unnecessary architectural complexity and governance burden.

An operator is also a poor candidate when source data is unreliable, decision responsibility is unclear, the workflow cannot be adequately monitored, or errors could create serious consequences before intervention is possible. The goal should be the minimum autonomy required to remove unnecessary work safely. Additional autonomy should be introduced only when there is a measurable operational benefit and sufficient evidence to support it.

Where This Is Heading

The next phase of AI adoption in pharma is likely to focus less on isolated model capability and more on controlled execution. Organizations will increasingly need to determine which workflows are suitable for agentic execution, which actions can safely be automated, where qualified people must remain accountable, and how identity, permissions, monitoring, validation, and escalation should be designed. These questions move the conversation from whether a model can produce an impressive response to whether an AI-enabled workflow can operate reliably within enterprise and regulatory constraints.

The organizations that gain the most from this shift may therefore not be those that deploy the greatest number of models. They are more likely to be those that treat orchestration, governance, permissions, evaluation, security, and human checkpoints as integral parts of the system rather than controls added after deployment.

Conclusion

The operator layer is not simply a larger AI model with a new label. It represents the connection between the predictions and recommendations pharma can increasingly generate and the enterprise systems where those insights need to become controlled action. That action might involve updating a CRM record, assembling a medical information response, flagging a clinical site, preparing an evidence package, or supporting a regulatory document workflow. The opportunity is greatest where work is high volume, source information is well governed, actions can be clearly bounded, and qualified reviewers already own the consequential decisions.

Building responsibly means starting with a narrow context of use, defining permissions, evaluating systems before granting production autonomy, recording system actions, measuring workflow outcomes, and retaining qualified people at the checkpoints that matter. Done well, AI operators can reduce the friction between insight and execution without removing the governance that regulated work requires. The first question should therefore not be which model to buy. It should be which workflow is worth changing, which actions can safely be delegated, and where human judgment must remain.

Author’s Note: This article was supported by AI-based research and writing, with Claude 4.5 assisting in the creation of text and images.